A description is given of the use of a nanodispersion, which comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (.alpha.) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (.beta.) adding the liquid obtained in step (.alpha.) to the water phase of the pharmaceutical end formulations, steps (.alpha.) and (.beta.) being carried out without any additional supply of energy. The nanodispersions used according to this invention are suitable as transport vehicles for pharmaceutical active agents.